196 related articles for article (PubMed ID: 31483418)
1. Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer.
Ziliotto S; Gee JMW; Ellis IO; Green AR; Finlay P; Gobbato A; Taylor KM
Metallomics; 2019 Sep; 11(9):1579-1592. PubMed ID: 31483418
[TBL] [Abstract][Full Text] [Related]
2. ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer Cells.
Taylor KM; Vichova P; Jordan N; Hiscox S; Hendley R; Nicholson RI
Endocrinology; 2008 Oct; 149(10):4912-20. PubMed ID: 18583420
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of zinc channel ZIP7 drives MAPK, PI3K and mTOR growth and proliferation signalling.
Nimmanon T; Ziliotto S; Morris S; Flanagan L; Taylor KM
Metallomics; 2017 May; 9(5):471-481. PubMed ID: 28205653
[TBL] [Abstract][Full Text] [Related]
4. The importance of targeting signalling mechanisms of the SLC39A family of zinc transporters to inhibit endocrine resistant breast cancer.
Jones S; Farr G; Nimmanon T; Ziliotto S; Gee JMW; Taylor KM
Explor Target Antitumor Ther; 2022 Apr; 3(2):224-239. PubMed ID: 35591900
[TBL] [Abstract][Full Text] [Related]
5. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
6. Zinc transporter ZIP7 is a novel determinant of ferroptosis.
Chen PH; Wu J; Xu Y; Ding CC; Mestre AA; Lin CC; Yang WH; Chi JT
Cell Death Dis; 2021 Feb; 12(2):198. PubMed ID: 33608508
[TBL] [Abstract][Full Text] [Related]
7. A distinct role in breast cancer for two LIV-1 family zinc transporters.
Taylor KM
Biochem Soc Trans; 2008 Dec; 36(Pt 6):1247-51. PubMed ID: 19021534
[TBL] [Abstract][Full Text] [Related]
8. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
9. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7.
Taylor KM; Hiscox S; Nicholson RI; Hogstrand C; Kille P
Sci Signal; 2012 Feb; 5(210):ra11. PubMed ID: 22317921
[TBL] [Abstract][Full Text] [Related]
11. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
[TBL] [Abstract][Full Text] [Related]
12. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.
Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G
Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103
[TBL] [Abstract][Full Text] [Related]
13. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
[TBL] [Abstract][Full Text] [Related]
14. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
15. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth.
Catalano S; Giordano C; Panza S; Chemi F; Bonofiglio D; Lanzino M; Rizza P; Romeo F; Fuqua SA; Maggiolini M; Andò S; Barone I
Breast Cancer Res Treat; 2014 Jul; 146(2):273-85. PubMed ID: 24928526
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells.
Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW
Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of FGFR3 actions in endocrine resistant breast cancer.
Tomlinson DC; Knowles MA; Speirs V
Int J Cancer; 2012 Jun; 130(12):2857-66. PubMed ID: 21792889
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.
Elias D; Vever H; Lænkholm AV; Gjerstorff MF; Yde CW; Lykkesfeldt AE; Ditzel HJ
Oncogene; 2015 Apr; 34(15):1919-27. PubMed ID: 24882577
[TBL] [Abstract][Full Text] [Related]
20. MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERα expression and AKT activation.
Liang YK; Zeng D; Xiao YS; Wu Y; Ouyang YX; Chen M; Li YC; Lin HY; Wei XL; Zhang YQ; Kruyt FA; Zhang GJ
Cancer Lett; 2017 Feb; 386():65-76. PubMed ID: 27838413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
